Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing
Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2896-2900
DOI: 10.1093/jac/dkae302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 11.09.2024. Verfasst von Fiona Clarke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Antifungal Agents, Echinocandins, Candidiasis, Ambulatory Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australia National Health & Medical Research Council Investigator Grant.
Abstract (Originalsprache)
Background
Outpatient parenteral antimicrobial therapy (OPAT) can deliver extended parenteral treatment of fungal infections in an ambulatory setting, whilst minimizing treatment burden and cost. The extended dosing interval of rezafungin may potentiate the benefits of OPAT.
Methods
This retrospective cohort study includes all adult patients who received echinocandin therapy in a large OPAT programme between 2012 and 2022. Patient characteristics, treatment and outcomes were studied. Data were analysed to determine the effects of replacing daily dosing with weekly dosing of echinocandin.
Results
Across the study period, 11% (44/386) of all patients in our Health Service treated with ≥7 days of echinocandin were managed via OPAT. All were Candida and related ‘yeast-like’ species infections. Nakaseomyces glabrata (20/41; 49%) was the most common pathogen, fungaemia the most common presentation (17/41; 41%) and azole resistance the most frequent indication for echinocandin use (21/41; 51%). In total, 633 days of echinocandin were administered as OPAT. Thirteen patients (13/41; 32%) received concurrent parenteral antibacterials. Treatment success was achieved in 30/41 (73%) patients. If daily echinocandin dosing was replaced with weekly dosing, a potential 52% (633 to 326) reduction in the total number of treatments (for any therapy) delivered by the OPAT team is possible. The ongoing need for daily antibacterial administration mitigated the benefit in some of this cohort.
Conclusions
Echinocandin therapy can be safely delivered via OPAT with outcomes equivalent to bed-based care. The extended dosing interval of rezafungin will allow for a substantial reduction in the number of treatments required across the patient cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
- Monash Doctors, Monash Health, Clayton, Victoria, Australia.
- Pharmacy Department, Monash Health, Clayton, Victoria, Australia.
- Hospital in the Home, Monash Health, Clayton, Victoria, Australia.
- Department of Microbiology, Monash Health, Clayton, Victoria, Australia.
- Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health, Clayton, Victoria, Australia.
ORCID-Profile: Benjamin Rogers
Förderung
- Australia National Health & Medical Research Council Investigator Grant
Zitieren
APA
Clarke, F., Grenfell, A., Chao, S., Richards, H., Korman, T., & Rogers, B. (2024). Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing. Journal of Antimicrobial Chemotherapy, 79(11), 2896-2900. https://doi.org/10.1093/jac/dkae302
Vancouver
Clarke F, Grenfell A, Chao S, Richards H, Korman T, Rogers B. Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing. Journal of Antimicrobial Chemotherapy. 2024;79(11):2896-2900. doi:10.1093/jac/dkae302
BibTeX
@article{Clarke2024,
author = {Clarke, Fiona and Grenfell, Adelaide and Chao, Sarah and Richards, Helen and Korman, Tony and Rogers, Benjamin},
title = {Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {11},
pages = {2896--2900},
doi = {10.1093/jac/dkae302}
}
EUVIMED